Quarterly report pursuant to Section 13 or 15(d)

OPERATING SEGMENTS - Narrative (Details)

v3.23.1
OPERATING SEGMENTS - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Apr. 01, 2022
Segment Reporting Information [Line Items]    
Our proportionate share of unusual or infrequent items charge/(gain) recorded by equity method investees $ 82 $ (5)
Gain (Loss) on Sale of Previously Unissued Stock by Equity Investee   (24)
Productivity and Reinvestment    
Segment Reporting Information [Line Items]    
Productivity, integration and restructuring initiatives 27 10
BodyArmor    
Segment Reporting Information [Line Items]    
Gain (loss) related to BodyArmor transaction (4) 5
North America Segment    
Segment Reporting Information [Line Items]    
Productivity, integration and restructuring initiatives 18  
Business Exit Costs   12
North America Segment | Operating Income (Loss)    
Segment Reporting Information [Line Items]    
Business Exit Costs 6 11
North America Segment | BodyArmor    
Segment Reporting Information [Line Items]    
Gain (loss) related to BodyArmor transaction   19
Asia Pacific    
Segment Reporting Information [Line Items]    
Our proportionate share of unusual or infrequent items charge/(gain) recorded by equity method investees 140  
Bottling investments    
Segment Reporting Information [Line Items]    
Our proportionate share of unusual or infrequent items charge/(gain) recorded by equity method investees (58) (5)
Corporate    
Segment Reporting Information [Line Items]    
Gain (Loss) on Disposition of Business 439  
Debt and Equity Securities, Gain (Loss) 113 (104)
Gain (Loss) on Sale of Previously Unissued Stock by Equity Investee   24
Corporate | Productivity and Reinvestment    
Segment Reporting Information [Line Items]    
Productivity, integration and restructuring initiatives 27 10
Corporate | fairlife    
Segment Reporting Information [Line Items]    
Contingent Consideration Liability 62 22
Corporate | BodyArmor    
Segment Reporting Information [Line Items]    
Gain (loss) related to BodyArmor transaction $ (4) $ (14)